公开(公告)号：US20200054635A1

公开(公告)日：2020-02-20

申请号：US16606833

申请日：2018-04-20

Applicant: Epizyme, Inc.

Inventor： John Emmerson CAMPBELL ,  Kenneth William DUNCAN ,  Maria Alejandra RAIMONDI ,  Christine KLAUS ,  Elayne PENEBRE

IPC: A61K31/506 ,  A61K31/203 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/496 ,  A61K31/517 ,  A61K31/519 ,  A61K31/706 ,  A61P35/00

Abstract: The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.

公开(公告)号：US20180072702A1

公开(公告)日：2018-03-15

申请号：US15492506

申请日：2017-04-20

Applicant: Epizyme, Inc.

Inventor： Kevin Wayne KUNTZ ,  Edward James OLHAVA ,  Richard CHESWORTH ,  Kenneth William DUNCAN

IPC: C07D401/12 ,  C07D471/04 ,  C07D413/14 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14

CPC classification number: C07D401/12 ,  A61P35/00 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04

Abstract: The present invention relates to substituted 6,5-fused bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof.